drugset / Trial / NCT01406574
Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
Non-randomizedFactorialOpen-labelTreatment
Summary
The purpose of this study is: Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy
Timeline
- Start
- 2011-07
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OPB-31121 | Unknown | 400 mg | Oral |
| Subject | OPB-31121 | Unknown | 600 mg | Oral |